About Clinertia
Built so good studies keep moving.
We are a Contract Research Organisation based in Karachi, delivering clinical trials in Pakistan for pharmaceutical, biotech, device and academic sponsors — to the standards those sponsors are inspected against.
clin·er·tia
Why “Clinertia”
Clinical, and inertia — the tendency of a body in motion to stay in motion.
Most trials lose their momentum in the same places: a regulatory query nobody saw coming, a site that enrols fast and documents slowly, a data cut that surfaces problems weeks too late. We are built around those failure points, so a study that starts well keeps moving.
Vision
To be the clinical research partner sponsors trust to run studies in Pakistan — and the reason more global trials include patients from this region at all.
Mission
To deliver clinical trials that meet international standards of quality and data integrity, while widening access to investigational treatment for patients across Pakistan.
Values
The rules we operate to.
Not aspirations on a wall — the working principles that decide what happens when a timeline, a budget and a patient's interests pull in different directions.
- 01
Quality
ICH-GCP is the floor, not the target. Processes are written to survive an inspection on any given day, not to be prepared for one.
- 02
Integrity
Data is reported as observed. Timelines are quoted as achievable. Where a study is not feasible, we say so before the contract, not after.
- 03
Patient focus
Participants carry the risk in every trial. Consent is genuinely informed, burden is minimised, and safety questions are answered by a physician, quickly.
- 04
Partnership
Sponsors get a named team with real decision authority, not a rotating contact list and a monthly status deck.
- 05
Responsiveness
Sites and sponsors both operate on clocks. Queries, escalations and approvals move on defined turnaround times.
- 06
Accountability
When something slips, it is surfaced early with a plan attached. Problems get smaller when they are visible.
Standards
Built to be inspected.
Our processes, systems and deliverables are designed around the regulatory and data standards that sponsors, regulators and ethics committees audit against.
ICH-GCP E6(R3)
Good Clinical Practice
DRAP
Drug Regulatory Authority of Pakistan
NBC
National Bioethics Committee
21 CFR Part 11
Electronic records & signatures
CDISC SDTM / ADaM
Submission data standards
MedDRA
Adverse event coding
WHO-DD
Medication coding
ICH E2A–E2F
Safety reporting
How we deliver
Five stages. Named owners.
- 01
Feasibility
Protocol review, site and country assessment, and an enrolment projection we are prepared to be held to.
- 02
Start-up
Parallel regulatory, ethics and site contracting tracks, driven against a start-up critical path.
- 03
Conduct
Risk-based monitoring, active site management, and enrolment reporting you can act on weekly.
- 04
Data & analysis
Continuous cleaning, coding and reconciliation, then analysis against a pre-agreed statistical plan.
- 05
Close-out
Site close-out, archiving, final study report contributions and an inspection-ready trial master file.
Next step
Tell us about your study. We’ll show you how it moves.
Share a synopsis-level summary — indication, phase, target enrolment and timeline. We come back with scope, assumptions and an indicative budget.